

PROGRAMME

Wednesday, 25th September 2024, Lansdowne Suite, Herbert Park Hotel

Registration from 08:30

RCPI external CPD credits: pending

09:00 – 09:15 Welcome and Introduction – Prof John Crown, St. Vincent’s Hospital, Dublin

TARGETED THERAPIES - LARGE MOLECULE: Session Chair – Prof. Sara Hurvitz, Fred Hutch Cancer Center

09:15 – 09:45 **Revisiting CD47 as a therapeutic target in solid tumour malignancies**
Dr. Mark Pegram, Susy Yuan-Huey Hung Prof Med Oncology, Stanford University School of Medicine

09:45 – 10:15 **Biomarkers of response and resistance to Antibody Drug Conjugates: translational insights**
Dr. Aditya Bardia, David Geffen School of Medicine UCLA and the UCLA Health Jonsson CCC

10:15 – 10:45 **Zanidatamab: A novel HER-2 directed biparatopic monoclonal antibody and its development in breast and other tumors**
Dr. Debasis Chakrabarti, Global Development Lead, Executive Director, Hematology and Oncology Clinical Development, Jazz Pharmaceuticals, Philadelphia

10:45 – 11:00 *Coffee break*

TARGETED THERAPIES - SMALL MOLECULE: Session Chair – Prof. Sara Hurvitz, Fred Hutch Cancer Center

11:00 – 11:30 **Tucatinib, a Reversible HER2 TKI, Augments the Activity of Trastuzumab and HER2-Targeting ADCs Through a Unique Mechanism of Action**
Dr. Anita Kulukian, Senior Principal Scientist, Pfizer

11:30 – 12:00 **Phase 3 postMONARCH trial of Abemaciclib+fulvestrant vs fulvestrant alone for HR+, HER2-advanced breast cancer (ABC) following progression on prior CDK4/6 inhibitor plus endocrine therapy and Phase Ia/Ib EMBER study of Imlunestran, an oral SERD, as Monotherapy and in Combination With Targeted Therapy in ER+, HER2- ABC**
Dr. Lillian Smith, Sr. Vice President, Global Development Head, Breast Cancer, Loxo@Lilly, Eli Lilly

12:00 - 12:30 **Targeting the PI3K/Akt/mTOR Pathway: PIKing the right strategy**
Dr. Komal Jhaveri, Section Head, Endocrine Therapy Research Program; Clin. Dir., Early Drug Dev. Service; Patricia & James Cayne Chair for Junior Faculty, MSKCC
12:30 – 13:30 *Lunch*

BREAST CANCER: Session Chair – Prof. John Crown, St Vincent’s Hospital; DCU; UCD

13:30 – 14:00 **Radioligand therapy and solid tumours**
Dr. Eirini Pectasides, Clinical Program Leader, Novartis Institutes for BioMedical Research

14:00 – 14:30 **Copper depletion as therapeutic strategy for triple negative breast cancer: Updates**
Dr. Linda T. Vahdat, Deputy Director, Section Chief, Med Onc, Hematology, Dartmouth Cancer Center

KEYNOTE PRESENTATION

14:30 – 15:15 **Translational Implications of New ADC Targets in Breast Cancer and CDK 4/6 Update**
Dr. Dennis J. Slamon, 2019 Lasker Award Winner, Director of Clinical/Translational Research, Director of the Revlon/UCLA Women’s Cancer Research Program at JCCC. Professor of Medicine, Chief, Division of Hematology/Oncology.

15:15 - 15:30 *Coffee break*

GI AND COLON CANCER: Session Chair – Prof. John Crown, St Vincent’s Hospital; DCU; UCD

15:30 - 16:00 **Pancreas Cancer: Novel therapeutics for today and tomorrow**
Dr. Eileen O’Reilly, MSKCC, Prof Medicine, Weill Cornell Medicine

16:00 – 16:30 **Advanced HCC: TKI, PD(l)-1, CTLA-4 and more**
Dr. Richard Finn, Division of Hematology/Oncology, David Geffen School of Medicine, UCLA

16:30-17:00 **Systemic Therapy for Biliary Cancers: Who is First?**
Dr. Ghassan Abou-Alfa, MSKCC, Prof, Cornell University, Adj Prof Med Diplomacy, Trinity College Dubli

The organisation of this meeting has been funded by third party sponsors, however, none of these sponsors have had any influence over the educational/scientific content of presentations or the agenda of the meeting.

FOR ALL SOCIAL MEDIA PLEASE INCLUDE #TRANSONCXVII

17TH INTERNATIONAL SYMPOSIUM ON TRANSLATIONAL RESEARCH IN ONCOLOGY



Thursday, 26th September 2024, Lansdowne Suite, Herbert Park Hotel

Registration from 08:30

RCPI external CPD credits: pending

BiTES/T-CELL ENGAGERS: Session Chair – Prof. Mario Sznol, Yale School of Medicine

- 09:00 - 09:30 **Advances in developing ImmTAC molecules: pioneering soluble TCR-based bispecifics**
Dr Annelise Vuidepot, SVP – CTO and Head of Pipeline & Platform research, Immunocore
- 09:30 - 10:00 **How to Increase the Impact of BiTE® Immune Therapy in Solid Tumors**
Dr Pablo Martinez Rodriguez, Executive Medical Director for Global Development, Amgen
- 10:00 - 10:30 **Tumor-targeted costimulation via CD28 bispecific antibodies: Turning immunotherapy “cold” tumors “hot”**
Dr. Janelle Waite, Director, Cancer Immunology Research, Regeneron Pharmaceuticals
- 10:30 - 10:45 **Discussion session**
- 10:45 – 11:00 **Coffee break**

IMMUNOTHERAPY: Session Chair – Prof. Mario Sznol, Yale School of Medicine

- 11:00 - 11:30 **Tumor Infiltrating Lymphocyte therapy in Solid Tumors—Focus on Next Generation TIL Treatment**
Dr. Rodabe Amaria, Melanoma Medical Oncologist, MD Anderson Cancer Center

KEYNOTE PRESENTATION

11.30 – 12:15 **Beyond Immune Checkpoint Blockade: Emerging Strategies**

Prof. Tak Mak, Director, Campbell Family Institute for Breast Cancer Research, Department of Medical Biophysics, Ontario Cancer Institute of Princess Margaret Hospital; Professor, Department of Immunology, University of Toronto

12:15 – 13:15 **Lunch**

IMMUNOTHERAPY – VACCINES: Session Chair – Prof. John Crown, St Vincent’s Hospital; DCU; UCD

- 13:15 – 13:45 **Cancer Vaccines: From Treatment to Prevention**
Prof. Nora Disis, Clinical Research Division, Fred Hutch Cancer Centre
- 13:45 – 14:15 **Arenavirus-based Immunotherapy to Target Cancer**
Dr. Thomas Bogenrieder, CMO, Abalos Therapeutics
- 14:15 – 14:45 **Oncolytic Immunotherapy in Oncology: focus on melanoma**
Dr. Giuseppe Gullo, Executive Medical Director, Clinical Development, Replimune
- 14:45 – 15:00 **Coffee break**

BIOMARKERS: Session Chair – Prof. William Gallagher, AICRI & University College Dublin

- 15:00 – 15:30 **AI for biomarker development, deployment, and validation**
Jeff Leek, Chief Data Officer, VP, J.Orin Edson Foundation Chair of Biostatistics, Fred Hutchinson Cancer Center
- 15:30 – 16:00 **Extracellular Vesicles and their Cargo: key biomarkers in liquid biopsies or too early to say?**
Prof. Lorraine O’Driscoll, School of Pharmacy & Pharmaceutical Sciences, Trinity College Dublin
- 16:00– 16:30 **Decoding heterogeneity in TNBC: many shades of p53 mutants**
Prof. Joshua LaBaer, Executive Director, Bidesign Institute, Arizona State University

The organisation of this meeting has been funded by third party sponsors, however, none of these sponsors have had any influence over the educational/scientific content of presentations or the agenda of the meeting.

FOR ALL SOCIAL MEDIA PLEASE INCLUDE #TRANSONCXVII

17TH INTERNATIONAL SYMPOSIUM ON TRANSLATIONAL RESEARCH IN ONCOLOGY



Friday 27th September 2024, Lansdowne Suite, Herbert Park Hotel

Registration from 8:30

RCPI external CPD credits: pending

TUMOUR MICROENVIRONMENT I: Session Chair – Prof Robert Kerbel, University of Toronto

- 09:00 - 09:30 **Immune-Mediated Extracellular Matrix Remodeling Promotes Tumor Resistance and Metastasis Following Anti-Cancer Therapy**
Prof. Yuval Shaked, Dept of Cell Biology and Cancer Science, Rappaport Faculty of Medicine, Technion, Israel. Director of the Rappaport-Technion Integrated Cancer Center
- 09:30 - 10:00 **Vaccination against the tumor vasculature - an anti-angiogenic adjuvant to immunotherapy**
Prof. Arjan Griffioen, Head of the Angiogenesis Laboratory, Amsterdam UMC
- 10:00 - 10:30 **Making tumors vulnerable to immunity via optimized drug combinations**
Prof. Patrycja Nowak-Sliwinska, Head of Molecular Pharmacology Group, Vice-president of the School of Pharmaceutical Sciences, University of Geneva
- 10:30 – 10:45 *Coffee break*

TUMOUR MICROENVIRONMENT II: Session Chair – Prof Robert Kerbel, University of Toronto

- 10:45– 11:15 **The rising interest in using oncology drugs below the MTD: contribution of TME modulations in maintaining efficacy**
Prof. Robert Kerbel, Sunnybrook Research Institute, University of Toronto
- 11:15 – 11:45 **Reviving the Clinical Potential of Patient Derived Xenografts for Evaluating Immunotherapies By Using Chick Embryos**
Dr. Hon Leong, Dept Medical Biophysics, Sunnybrook Research Institute, University of Toronto

KEYNOTE PRESENTATION

- 11:45 - 12:30 **Perspectives on the role of Innate immunity in the tumor microenvironment**
Prof. Pam Ohashi, Director, Tumor Immunotherapy Program, Princess Margaret Cancer Centre
- 12:30 – 13:30 *Lunch*

IMMUNOTHERAPY: NEOADJUVANT V'S ADJUVANT

Session Chair – Dr. Dimitrios Tryfonopoulos, Medical Oncologist, Saint Savvas Anticancer Hospital, Athens

- 13:30 - 14:00 **Immunotherapy Neoadjuvant v's Adjuvant: Breast cancer**
Dr. Lajos Pusztai, Professor of Medicine, Yale University and Director of Breast Cancer Translational Research and Co-Director of the Cancer Center Genomics, Genetics, and Epigenetics Program
- 14:00 – 14:30 **Immunotherapy Neoadjuvant v's Adjuvant: Melanoma**
Prof. John Haanen, Medical Oncology Dept. Netherlands Cancer Institute
- 14:30 - 15:00 **Immunotherapy Neoadjuvant v's Adjuvant: Lung cancer**
Dr. Patrick Forde, Trinity St James Cancer Institute, Trinity College Dublin
- 15:00– 15:15 *Coffee break*

MUTANT KRAS, MUTANT P53 & MYC OVEREXPRESSION: FROM UNDRUGGABLE TO DRUGGABLE

Session Chair – Prof Joe Duffy, St. Vincent's University Hospital; University College Dublin

- 15:15 – 15:45 **Drugging Difficult to Target Genes: Where are We? Where are We Going?**
Prof. Michael J. Duffy, Clinical Research Centre, St. Vincent's University Hospital, Dublin.
- 15:45 - 16:15 **Innovative strategies for targeting the undruggable p53 in cancer therapy**
Dr. Ecaterina Dumbrava, Dept. Investigational Cancer Therapeutics, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center.
- 16:15 – 16:45 **Drugging Undruggable: Targeting MYC-driven Cancers with a Molecular Glue Degradator**
Dr. Filip Janku, CMO, Monte Rosa Therapeutics

The organisation of this meeting has been funded by third party sponsors, however, none of these sponsors have had any influence over the educational/scientific content of presentations or the agenda of the meeting.

FOR ALL SOCIAL MEDIA PLEASE INCLUDE #TRANSONCXVII